Last $53.35 USD
Change Today +1.18 / 2.25%
Volume 1.3M
AMSG On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

amsurg corp (AMSG) Snapshot

Open
$52.28
Previous Close
$52.18
Day High
$53.93
Day Low
$52.28
52 Week High
09/2/14 - $54.48
52 Week Low
05/9/14 - $40.00
Market Cap
2.6B
Average Volume 10 Days
536.8K
EPS TTM
$2.10
Shares Outstanding
48.1M
EX-Date
--
P/E TM
25.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for AMSURG CORP (AMSG)

amsurg corp (AMSG) Related Bloomberg News

View More Bloomberg News

amsurg corp (AMSG) Related Businessweek News

No Related Businessweek News Found

amsurg corp (AMSG) Details

AmSurg Corp., through its subsidiaries, acquires, develops, and operates ambulatory surgery centers (ASC) in partnership with physicians in the United States. Its surgery centers perform colonoscopy and other endoscopy procedures in the areas of gastroenterology; cataracts and retinal laser surgeries in the area of ophthalmology; and knee and shoulder arthroscopy and carpal tunnel repair in the area of orthopedics. As of December 31, 2013, the company operated 151 centers for gastrointestinal endoscopy procedures, 48 multi specialty centers, 36 centers for ophthalmology surgery procedures, and 7 centers for orthopedic procedures. It offers its surgery center services directly to patients; referring physicians; and third-party payors, including health maintenance organizations, preferred provider organizations, other managed care organizations, and employers. The company was founded in 1992 and is based in Nashville, Tennessee.

4,100 Employees
Last Reported Date: 06/30/14
Founded in 1992

amsurg corp (AMSG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $736.5K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $442.0K
President of Ambulatory Services
Total Annual Compensation: $350.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $442.0K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

amsurg corp (AMSG) Key Developments

AmSurg Corp. Declares Quarterly Preferred Stock Dividend, Payable on January 1, 2015

AmSurg Corp. announced that its Board of Directors has declared a quarterly dividend of $1.3125 per share in cash for the Company's 5.250% Mandatory Convertible Preferred Stock, Series A-1. The dividend is payable on January 1, 2015 to shareholders of record as of December 15, 2014.

AmSurg Corp. Announces Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2014.; Provides Earnings Guidance for the Fourth Quarter and Full Year of 2014

AmSurg Corp. announced unaudited consolidated earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported revenue of $503.2 million, up 91.3% from $263.04 million in the same quarter last year. Net loss and attributable to the company's common shareholders were $12.07 million or $0.23 loss per share, compared with the prior-year period's net earnings attributable to the company's common shareholders of $16.77 million or $0.53 per share. Adjusted net earnings were $34.6 million or $0.69 per share, ex one-time items, versus $17.99 million or $0.56 per share in the same quarter the previous year. Operating income was $95,065,000 against $79,982,000 a year ago. Earnings from continuing operations before income taxes were $39,123,000 against $72,689,000 a year ago. Net earnings from continuing operations were $39,105,000 against $61,528,000 a year ago. Loss from continuing operations, net of income tax attributable to the company were $10,704,000 against earnings from continuing operations, net of income tax attributable to the company $16,659,000 a year ago. Diluted net loss from continuing operations attributable to the company were $0.23 against diluted net earnings from continuing operations attributable to the company of $0.52 a year ago. Diluted net loss attributable to the company were $0.26 against diluted net earnings attributable to the company of $0.52 a year ago. EBITDA was $51,474,000 against $43,352,000 for the same period in the last year. Adjusted EBITDA was $95,887,000 against $45,566,000 a year ago. Net cash flows provided by operating activities were $122,470,000 against $96,383,000 a year ago. Acquisition of property and equipment was $8,098,000 against $8,239,000 a year ago. For the nine months, the company reported revenues of $544,212,000 against $525,291,000 a year ago. Operating income was $262,794,000 against $245,500,000 a year ago. Earnings from continuing operations before income taxes were $192,998,000 against $223,154 a year ago. Net earnings from continuing operations were $167,126,000 against $187,439,000 a year ago. Net earnings and attributable to the company's common shareholders was $24,083,000 against $53,145,000 a year ago. Earnings from continuing operations, net of income tax attributable to the company were $25,569,000 against $52,192,000 a year ago. Diluted net earnings from continuing operations attributable to the company were $0.69 against $1.64 a year ago. Diluted net earnings attributable to the company were $0.65 against $1.67 a year ago. EBITDA was $144,209,000 against $134,405,000 for the same period in the last year. Adjusted EBITDA was $193,754,000 against $138,523,000 a year ago. Adjusted net earnings were $74,627,000 or $1.95 per share against $54,658,000 or $1.71 per share a year ago. Net cash flows provided by operating activities were $276,051,000 against $248,933,000 a year ago. Acquisition of property and equipment was $23,109,000 against $20,711,000 a year ago. The company provided earnings guidance for the fourth quarter and full year of 2014. For quarter, the company expects adjusted EPS of $0.70-$0.73. The company sees fiscal 2014 adjusted EPS of $2.66 - $2.71 on revenue of $1.60 billion - $1.61 billion, revenues in a range of $1.60 billion to $1.61 billion, net cash flow provided by operating activities, less distributions to non-controlling interests, in a range of $235 million to $245 million, excluding transaction costs.

Amsurg Corp. Announces Changes to Executive Management

AmSurg Corp. announced changes to the Company's executive management as part of the integration of Sheridan. Phillip A. Clendenin, formerly the Executive Vice President - Operations of AmSurg, has been named President - Ambulatory Services. Robert Coward, formerly President of Sheridan, has been named President - Physician Services and Chief Development Officer for the Company. In addition, the Company announced that David L. Manning, Executive Vice President and Chief Development Officer of the Company, will be leaving the Company effective December 31, 2014. Phillip has a long and successful background in healthcare, including as Senior Vice President of Corporate Services, Senior Vice President - Operations and Executive Vice President - Operations of AmSurg. The company recently welcomed Bob to AmSurg as a result of the acquisition of Sheridan, where he has served as President since 2010. Prior to becoming President, Bob served Sheridan as Chief Financial Officer and as Senior Vice President of Operations or Chief Operating Officer since 2000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMSG:US $53.35 USD +1.18

AMSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Civitas Solutions Inc $16.30 USD +1.24
HealthSouth Corp $40.13 USD +0.59
National Healthcare Corp $63.00 USD -0.62
Providence Service Corp/The $36.50 USD -0.40
Surgical Care Affiliates Inc $32.15 USD -0.70
View Industry Companies
 

Industry Analysis

AMSG

Industry Average

Valuation AMSG Industry Range
Price/Earnings 39.8x
Price/Sales 1.8x
Price/Book 1.7x
Price/Cash Flow 27.8x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMSURG CORP, please visit www.amsurg.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.